KELOWNA, BC - Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), a leader in drug delivery platforms, announced results from a human pilot study indicating that its DehydraTECH-processed Rybelsus® capsules have improved tolerability compared to commercially available Rybelsus® tablets. The study, which focused on the delivery of the GLP-1 drug semaglutide, found that individuals taking the DehydraTECH-treated capsules experienced fewer adverse events.
The study involved 9 participants who took the DehydraTECH-processed capsules and reported no adverse events, while 6 out of 9 subjects taking the standard Rybelsus® tablet experienced mild adverse events. Additionally, the study included an evaluation of a DehydraTECH-processed Rybelsus® formulation as a dissolvable mouth-melt tablet. Although this format delivered less drug into the bloodstream compared to the standard tablet, it showed potential for adding to the overall absorption of the drug.
The results build on previous findings from Lexaria's initial human pilot study, which also showed better tolerability for the DehydraTECH-processed capsules versus the standard tablets. These studies are part of Lexaria's ongoing efforts to improve drug delivery for oral medications.
Rybelsus® (semaglutide) is the only GLP-1 drug approved by the FDA for oral dosing to treat diabetes and weight loss. It is owned and manufactured by Novo Nordisk (NYSE:NVO)®. DehydraTECH™ is Lexaria's patented technology designed to enhance the delivery of active pharmaceutical ingredients (APIs) through oral routes.
The company suggests that the improved oral tolerability of the DehydraTECH-processed capsules could potentially lead to increased use of oral GLP-1 product formats in the future, pending definitive results from thorough clinical testing.
Lexaria operates a licensed in-house research laboratory and holds a portfolio of 46 granted patents, with more pending worldwide. The company remains focused on advancing its technology and conducting research to improve the efficacy and safety of drug delivery.
The information in this article is based on a press release statement from Lexaria Bioscience Corp. and has not been independently verified.
In other recent news, Lexaria Bioscience Corp. has made significant strides in its research initiatives. The company announced preliminary results from its human pilot study, GLP-1-H24-2, indicating a trend toward higher absorption of its DehydraTECH-processed Rybelsus compared to unprocessed Rybelsus. Additionally, Lexaria reported promising results from ongoing animal studies, suggesting potential benefits in diabetes management and weight loss efficacy through its DehydraTECH technology.
The company also announced successful outcomes from a joint research program with the National Research Council of Canada, focusing on DehydraTECH's effectiveness in processing the GLP-1 drug, semaglutide. In the financial sector, H.C. Wainwright maintained its Buy rating for Lexaria Bioscience, highlighting the potential of the DehydraTECH technology to significantly impact obesity and diabetes treatment.
Lexaria Bioscience has also expanded its management team, appointing Nelson Cabatuan as the consulting Chief Strategic Financial Advisor. Furthermore, the company has acquired two significant patents pertaining to the treatment of hypertension and epilepsy. These are recent developments, and further results from the ongoing studies are anticipated. As always, it's crucial for investors to remember that while these developments are promising, they are subject to further research and regulatory approvals.
InvestingPro Insights
Lexaria Bioscience Corp. (NASDAQ:LEXX) has been making strides with its DehydraTECH technology, aiming to improve the delivery and tolerability of oral medications. As the company advances its research and development, investors might also be interested in the financial health and market performance of Lexaria. According to recent data from InvestingPro, the company holds a market capitalization of approximately $46.17 million USD, suggesting a modest size within the biotech sector.
An InvestingPro Tip worth noting is that Lexaria has more cash than debt on its balance sheet, which is a positive sign for the company's financial stability. This could provide Lexaria with a cushion to fund ongoing research and development without the immediate need for external financing. Additionally, analysts anticipate sales growth in the current year, potentially reflecting confidence in the company's technology and market prospects.
On the performance front, Lexaria's stock has experienced significant volatility. While the stock has seen a high return over the last year, with a year-to-date price total return of 133.6%, it has fared poorly over the last month. This could indicate short-term market reactions to broader industry trends or specific company news.
InvestingPro also provides additional insights for those interested in a deeper analysis of Lexaria. Currently, there are 8 more InvestingPro Tips available on their platform, which could offer investors further guidance on the company's valuation and future prospects.
For those considering an investment in Lexaria or simply following the company's progress, these metrics and tips from InvestingPro can provide valuable context alongside the company's technological developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.